Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Leaving the nest
June 2019
SHARING OPTIONS:

MADISON, Wis.—April closed with the news that Nimble Therapeutics has begun operating as a standalone business, following its spinout from F. Hoffman La Roche, in order to commercialize its proprietary chemical synthesis technology. Nimble Therapeutics has also completed a Series A financing, which was led by Telegraph Hill Partners. The company plans to leverage its technology platform to speed the discovery and optimization of macrocyclic peptidomimetics as novel therapeutics. Nimble Therapeutics also intends to expand existing collaborations and pursue additional partnerships in key therapeutic areas.
 
Dr. Deval Lashkari, senior partner at Telegraph Hill Partners and board director at Nimble Therapeutics, said in part that “Nimble’s capabilities are truly revolutionary, and we are excited to work with the company in a shared vision to grow the business into a leading drug discovery partner for the pharmaceutical industry.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.